Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

BACKGROUND: Enzalutamide and abiraterone are new androgen-axis disrupting treatments for metastatic castration resistant prostate cancer (mCRPC). We examined response and outcomes of enzalutamide-treated mCRPC patients in the real-world context of prior treatments of abiraterone and/or docetaxel. ME...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Prostate Cancer Prostatic Dis
Hlavní autoři: Cheng, Heather H., Gulati, Roman, Azad, Arun, Nadal, Rosa, Twardowski, Przemyslaw, Vaishampayan, Ulka N., Agarwal, Neeraj, Heath, Elisabeth I., Pal, Sumanta K., Rehman, Hibba-tul, Leiter, Amanda, Batten, Julia A., Montgomery, R. Bruce, Galsky, Matthew D., Antonarakis, Emmanuel S., Chi, Kim N., Yu, Evan Y.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4430366/
https://ncbi.nlm.nih.gov/pubmed/25600186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2014.53
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky